Although azithromycin is extensively used in the treatment of respiratory tract infections as well as skin and skin-related infections, pharmacokinetics of azithromycin in extracellular space fluid of soft tissues, i.e., one of its therapeutic target sites, are not yet fully elucidated. In this study, azithromycin concentration-time profiles in extracellular space of muscle and subcutaneous adipose tissue, but also in plasma and white blood cells, were determined at days 1 and 3 of treatment as well as 2 and 7 days after the end of treatment. Of all compartments, azithromycin concentrations were highest in white blood cells, attesting for intracellular accumulation. However, azithromycin concentrations in both soft tissues were markedly lower than in plasma both during and after treatment. Calculation of the area under the concentration-time curve from 0 to 24 h (AUC 0 -24 )/MIC 90 ratios for selected pathogens suggests that azithromycin concentrations measured in the present study are subinhibitory at all time points in both soft tissues and at the large majority of observed time points in plasma. Hence, it might be speculated that azithromycin's clinical efficacy relies not only on elevated intracellular concentrations but possibly also on its known pleotropic effects, including immunomodulation and influence on bacterial virulence factors. However, prolonged subinhibitory azithromycin concentrations at the target site, as observed in the present study, might favor the emergence of bacterial resistance and should therefore be considered with concern. In conclusion, this study has added important information to the pharmacokinetic profile of the widely used antibiotic drug azithromycin and evidentiates the need for further research on its potential for induction of bacterial resistance.
T
he azalide antibiotic azithromycin is considered to have advantageous pharmacokinetic (PK), pharmacodynamic (PD), and safety and tolerability properties if compared to the older macrolides and is extensively used for the treatment of adult and pediatric respiratory tract infections as well as skin and skin-related infections, including sexually transmitted diseases (1, 2) . In addition to time-dependent bacteriostatic or bactericidal activity, which it shares with most other macrolides (3, 4) , azithromycin can also show concentration-dependent bactericidal activity against some organisms (5) and displays an important postantibiotic effect (6) .
Azithromycin is extensively distributed into tissues, as attested by a large volume of distribution of 23 liters/kg (7) . In this context, the most prominent feature of azithromycin is its ability to concentrate in intracellular compartments, mainly in fibroblasts, phagocytic cells, and other white blood cells (WBC) (8, 9) . Because of the drug's dibasic molecular structure, which is unique among the otherwise monobasic macrolide compounds, azithromycin is confined within the acidic lysosomes of WBC due to an ion-trapping mechanism. Subsequently, it is released only very slowly from intracellular compartments (10) . This is believed to account for the sustained drug concentrations in tissues which are reported to persist long after the end of therapy (11, 12) , as reflected by a long and biphasic elimination half-life of up to 5 days (7) . On the other hand, concern has been expressed about the presence of subinhibitory azithromycin concentrations in tissue after the end of therapy (13) , since they might trigger the emergence of bacterial resistance (14) .
It is important to mention that most bacterial infections take place in the interstitium, i.e., the extracellular space fluid of tissues (15, 16) . Hence, it is the drug concentration in this very compartment, i.e., at the target site, that determines the efficacy of an antibiotic and, if it is not sufficiently high, might drive the development of bacterial resistance.
So far, azithromycin concentrations have been measured in WBC and different tissue-specific phagocytes (17) (18) (19) , i.e., intracellular compartments, and in homogenized biopsy specimens obtained from lung tissue, lymph nodes, prostate, tonsils, and gastric tissue (11, 17, (20) (21) (22) (23) , where distinction between intracellular and extracellular concentrations is not possible. Azithromycin concentrations have also been determined in body fluids such as bronchoalveolar washing, gastric juice, sputum, and peritoneal dialysis fluid (17-19, 21, 24, 25) . However, despite interstitial skin and soft tissue infections constituting one of the drug's main therapeutic targets, data on azithromycin pharmacokinetics in the extracellular space of human soft tissues, such as muscle and subcutaneous adipose tissue, are still missing. Therefore, the present study was designed to measure the free, microbiologically active concentration-time profile of azithromycin in extracellular space fluid of muscle and subcutaneous adipose tissue of healthy volunteers, during and up to 7 days after the end of active treatment. Concentration-time profiles of azithromycin were also determined in plasma and WBC in order to better understand the drug's distribution processes. For this purpose, the microdialysis technique was employed, which allows for direct measurement of unbound drug concentrations in extracellular space fluid (26) . The information retrieved by this study might contribute to a better understanding of the tissue pharmacokinetics of azithromycin and its implications on the development of bacterial resistance.
MATERIALS AND METHODS

Regulatory issues.
This prospective, open-labeled PK study was conducted at the Department of Clinical Pharmacology in Vienna, Austria, in accordance with the actual ICH-GCP guidelines and the Declaration of Helsinki. The study was approved by the Ethics Committee of the Medical University of Vienna and authorized by the Austrian Agency for Health and Food Safety.
Subjects. Six healthy male volunteers were enrolled after a screening visit which included physical examination, blood sampling for hematology, clinical chemistry, virology, and coagulation tests, as well as electrocardiogram tracing and noninvasive arterial pressure measurement. Key inclusion criteria were male, age between 18 and 50 years, body mass index between 18 and 30, no regular concomitant medication within the last 2 weeks prior to the study day, and written informed consent. Key exclusion criteria were known allergy or hypersensitivity against azithromycin and clinically relevant abnormal physical or laboratory findings.
Intake of study drugs and PK sampling. Starting with study day 1, subjects received 500 mg of azithromycin (Zithromax; Pfizer Corporation, Austria) once daily for three consecutive days. Azithromycin was taken fastened, i.e., at least 2 h after the last intake of food and at least 1 h before the next intake of food. PK sampling was performed on study days 1 and 3 (i.e., after a single dose and on the last day of therapy and on study days 5 and 10 (i.e., 2 or 7 days after the end of therapy) for plasma, muscle tissue, subcutaneous adipose tissue, and WBC as described below.
Plasma sampling. Azithromycin concentrations in plasma were determined at baseline and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 h after drug administration on study days 1 and 3, as well as at three defined time points on days 5 and 10.
Microdialysis sampling. Azithromycin concentrations in muscle and subcutaneous adipose tissue were determined using the microdialysis technique. As described previously, this method is based on the exchange of analytes between the extracellular space of the tissue of interest and a microdialysis probe which is implanted into this tissue (26, 27) . Only free, i.e., non-protein-bound substances can diffuse across the semipermeable membrane located at the tip of the microdialysis probe and can be collected for subsequent analysis.
On study days, two microdialysis probes (CMA Microdialysis AB, Solna, Sweden) were aseptically inserted into skeletal muscle and subcutaneous adipose tissue of one thigh of each volunteer. The probes were then perfused with saline solution (NaCl 0.9%; Meditrade, Austria) at a flow rate of 1.5 l/min by a microinfusion pump. Microdialysis sampling was performed on study days 1, 3, 5, and 10 at defined time intervals. At the end of each sampling period, probes were calibrated by retrodialysis before removal. The retrodialysis method relies on the fact that the diffusion process across the semipermeable membrane is quantitatively equal in both directions. This implies that the fraction of the interstitial drug concentration which is recovered in the collected microdialysate sample, and is referred to as relative recovery, can be calculated according to the following equation: recovery (%) ϭ 100 Ϫ (100 ϫ analyte concentration out /analyte concentration in ). Interstitial azithromycin concentrations were calculated as follows: interstitial concentration ϭ 100 ϫ (sample concentration/relative recovery).
Isolation of WBC. Isolation of WBC was performed using Polymorphprep (Axis-Shilled PoC AS, Norway) according to the manufacturer's instructions. WBC were isolated from blood drawn at baseline and 2, 6, and 10 h after drug administration on study days 1 and 3, respectively, and at only one single time point on study days 5 and 10. For each sample, WBC count was performed by means of a hematology analyzer (Sysmex analyzer CE series 2100). To obtain the average concentration of azithromycin in WBC, the concentration measured in the sample was subsequently corrected for the total cell count and the cell volume as previously described (28) .
Sample analysis. Azithromycin concentrations in plasma, microdialysate, and WBC were determined by liquid chromatography-tandem mass spectrometry (LC-MS/MS) in analogy to a previously published method (29) . The lower limit of quantification (LLOQ) for azithromycin was 1.00 ng/ml in plasma and 0.500 ng/ml for analyses of microdialysate and WBC samples, and interday precision and accuracy were 4.6 Ϯ 2.8% and 100.3 Ϯ 3.4% (plasma) and 6.6 Ϯ 1.2% and 98.0 Ϯ 4.3% (microdialysate and WBC).
PK and statistical analyses. PK parameters were calculated using a commercially available computer program (Kinetica 3.0; Innaphase). Maximum plasma concentration (C max ), time to maximum plasma concentration (t max ), terminal elimination half-life (t 1/2 ), area under the concentration-time curve from 0 to 10 h (AUC 0 -10 ), and AUC 0 -24 were calculated from nonfitted data by employing the trapezoidal rule. For AUC 0 -24 , the concentration after 24 h was individually extrapolated based on the last observed concentration and the elimination constant k el . Additionally, apparent total body clearance (CL) and apparent volume of distribution (V) were calculated for plasma. AUC 0 -24 /MIC ratios were calculated for relevant pathogens. 2 ) were enrolled into and completed the study. Azithromycin was generally well tolerated. Two subjects reported headache, while dry eyes, gastrointestinal problems, hematoma, and tiredness were registered in one subject each. All adverse events but one were of mild character and resolved spontaneously. One case of moderate headache occurred, which required pharmacological treatment. No serious adverse event occurred.
RESULTS
Six
Concentration-time profiles of azithromycin in plasma, muscle, subcutis, and WBC during (i.e., days 1 and 3) and after the end of active treatment (i.e., days 5 and 10) are depicted in Fig. 1 , and key pharmacokinetic parameters of azithromycin during and after treatment are summarized in Table 1 . Azithromycin concentrations during active treatment were highest in WBC, with mean azithromycin C max in WBC exceeding C max in plasma more than 60-fold and C max levels in both muscle and subcutis more than 1,000-fold already on day 1. Despite generally higher azithromycin concentrations in all compartments on day 3, ratios of azithromycin C max in WBC to C max in other compartments still showed a marked increase on day 3 compared to that on day 1 ( Table 2) .
Even after the end of active treatment, azithromycin concentrations remained highest in WBC, with ratios of azithromycin C max in WBC to C max in other compartments showing a steady tendency to increase up to day 10, when C max in WBC exceeded C max in plasma almost 2,000-fold (Table 2) .
Both during and after the end of active treatment, azithromycin concentrations in plasma were markedly higher than in muscle and subcutis. Only on day 10 did drug levels seem to equilibrate between soft tissues and plasma. Azithromycin concentrations were quite comparable within both soft tissues at all time points.
In order to allow PK/PD-based estimates on clinical efficacy of azithromycin, AUC 0 -24 /MIC 90 ratios were calculated for all investigated compartments and days using four example organisms. Table 3 presents azithromycin AUC 0 -24 /MIC 90 ratios calculated for erythromycin-susceptible S. pneumoniae (azithromycin MIC, 0.125 g/ml), erythromycin-susceptible S. pyogenes (MIC, 0.25 g/ml), erythromycin-susceptible coagulase-negative Staphylococcus spp. (MIC, 1 g/ml), and erythromycin-susceptible S. aureus (MIC, 2 g/ml) (30).
DISCUSSION
In this study, PK profiles of azithromycin in plasma, muscle, subcutis, and WBC of healthy volunteers were assessed. Our work confirmed the potential for accumulation inside WBC previously reported for azithromycin. Importantly, azithromycin concentrations in soft tissues were markedly lower than in plasma and WBC during active treatment. In line with this finding, PK/PD calculations support the assumption that azithromycin concentrations observed in the present study might be subinhibitory in soft tissues and, at least partially, in plasma.
Of all investigated compartments, the highest azithromycin concentrations were detected in WBC. This is in good agreement with the existing evidence on azithromycin's capacity to accumulate inside WBC (25, (31) (32) (33) . In analogy, azithromycin WBC/ plasma concentration ratios observed in this study (Table 2) correspond to ratios mentioned in literature (34) . Strikingly, the azithromycin WBC/plasma ratio showed a strong increase even after the end of active treatment. All together, these findings confirm a previously discussed reservoir role of WBC for azithromycin. According to this hypothesis, it was speculated that WBC might transport the drug, which retains its antimicrobial properties in spite of being trapped inside lysosomal compartments (10, 35, 36) , to the site of infection and eventually release it in response to phagocytosis. Thus, WBC together with fibroblasts, which also constitute an important drug reservoir, contribute significantly to azithromycin's efficacy against intracellular pathogens (37, 38) .
The slow release of azithromycin from intracellular to extracellular compartments, as documented previously (37) , is believed to account for the sustained azithromycin tissue concentrations observed even after the end of treatment (12) . The findings of our study are basically consistent with this back distribution hypothesis per se, since azithromycin was constantly detectable in muscle and subcutis up to day 10. However, azithromycin soft tissue concentrations measured in the present study were substantially lower than in plasma and WBC both during and after active treatment. Only on day 10, i.e., 5 days after the last azithromycin dose, did drug concentrations seem to equilibrate between plasma and soft tissues. These findings are in marked contrast to the vast majority of data on tissue PK of azithromycin available in the literature so far, where azithromycin tissue concentrations are reported to remain on a high level even after the end of treatment and in any case to exceed drug concentrations in plasma (11, 12, 23, 38) .
In this context, it has to be noted that the term "tissue concen- tration" is sometimes used ambiguously. Many publications on azithromycin tissue PK report to measure tissue concentrations when most likely drug concentrations in fibroblasts and WBC, i.e., intracellular compartments, are actually meant (22, 39) . Also, a considerable number of animal and human studies refer to tissue concentrations as drug concentrations in tissue homogenates, making a distinction between intra-and extracellular compartment impossible (11, 17, 21, 40) . Other studies report azithromycin tissue concentrations but rely upon measurements of drug concentrations in specific body fluids like bronchoalveolar washing, gastric juice, sputum, or peritoneal dialysis fluid (21, 22, 24, 25) . Based on the findings of the present study, which to our knowledge is the first attempt to directly measure azithromycin drug levels in the extracellular space of muscle and subcutaneous adipose tissue in humans, calculation of AUC 0 -24 /MIC 90 ratios for relevant pathogens suggests that azithromycin concentrations are subinhibitory in both investigated soft tissues at all observed time points. The AUC 0 -24 /MIC 90 ratio is usually considered the major PK/PD determinant of in vivo efficacy of concentration-dependent antibiotics such as fluoroquinolones and aminoglycosides, but due to the drug's unique PK properties, it was postulated to apply also to azithromycin (41, 42) . A minimum plasma AUC 0 -24 /MIC 90 threshold of 10 has previously been reported as necessary for maximal clinical efficacy and bacterial killing of concentration-dependent antibiotics (43), but even higher thresholds are mentioned in the literature for specific organisms and diseases (41) . In this study, AUC 0 -24 /MIC 90 values above 10 were achieved only in plasma for highly susceptible organisms with azithromycin MIC values equal to or smaller than 0.25 g/ml (S. pneumoniae and S. pyogenes, MICs for azithromycin of 0.125 g/ml and 0.25 g/ml, respectively). Within soft tissues, exposure to azithromycin was constantly higher in muscle than in subcutis, where calculated AUC 0 -24 /MIC 90 ratios were lowest and did not exceed a maximum value of 2.32 during the entire observation period. The opposite was the case in WBC, where the lowest AUC 0 -24 /MIC 90 ratio was 170, calculated for S. aureus on day 10 ( Table 3) .
The presence of subinhibitory antibiotic concentrations at the target site is of significant concern. First, one might assume that it might be associated with treatment failure. Worryingly, despite the fact that in the present study azithromycin was administered Table 3 suggests that azithromycin efficacy against frequent causative organisms of skin and soft tissue infections (such as coagulase-negative staphylococci or Staphylococcus aureus) could be particularly low. On the other hand, no reports of significant numbers of clinical failures associated with azithromycin treatment are available in literature. A number of studies tested safety and efficacy of high-dose azithromycin for the treatment of several pediatric indications, including most notably respiratory tract infections and acute otitis media (45) (46) (47) . Unfortunately, we are not aware of comparable studies investigating the use of highdose azithromycin to treat skin and soft tissue infections. Hence, whether higher azithromycin doses might be superior to currently employed regimens in the treatment of skin and soft tissue infections caused by selected less susceptible pathogens must remain speculative. Furthermore, prolonged exposure of bacterial organisms to antibiotic drug levels below the MIC might trigger the development of bacterial resistance (14) . Resistance against macrolide antibiotics is increasing, and in this context it is important to mention that azithromycin use has been shown to possess higher potential for induction of resistance if compared to exposure to other macrolides such as clarithromycin (14, 48) . A possible induction of macrolide-resistant Streptococcus pneumoniae by longterm exposure to azithromycin was reported recently (49) .
On the other hand, we do currently not know if tissue concentrations can be used for investigation of PK/PD thresholds that have originally been obtained by use of plasma concentrations. The application of common PK/PD paradigms to the complex and heterogeneous group of macrolide antibiotics, and specifically to azithromycin, has been controversially discussed previously (10, 50) . Due to azithromycin's unique phagocyte-driven delivery to infection sites, anticipation of its clinical efficacy using PK/PD indices calculated by simply relating extracellular concentrations to MIC values may not be appropriate.
In particular, it has to be kept in mind that data collected in this study were measured in noninfected tissues of healthy volunteers under hemodynamically normal conditions and might not be pertinent for infected tissue or critically ill patients. On the one hand, increased blood flow and vascular permeability as well as enhanced chemotaxis of phagocytic cells are supposed to improve drug delivery to the site of infection. Inflammation-dependent increase of local azithromycin exposure has been previously shown in a study comparing azithromycin concentrations in inflammatory and noninflammatory skin blister fluid (33) . On the other hand, it has been shown that drug exposure to infected tissue in critically ill patients or patients with arterial occlusive disease might as well be significantly decreased by infection or otherwise triggered hemodynamic alterations (51) (52) (53) . In addition, there is evidence demonstrating that subinhibitory macrolide concentrations do still have an impact on a variety of bacterial virulence factors, including adhesion ability to epithelial cells, toxin production, and susceptibility to the host's immune defense (54) (55) (56) (57) . Also, macrolide antibiotics have been shown to possess beneficial anti-inflammatory and immunomodulatory properties which might be active even at concentrations below the MIC (58, 59) . Hence, it can be concluded that, at least in the case of azithromycin and other macrolide antibiotics, subinhibitory drug concentrations should not be considered an unambiguously negative phenomenon.
Taken together, this study has shown that azithromycin concentrations are subinhibitory in the extracellular space of soft tissues of healthy volunteers after oral administration of three daily 500-mg doses, as prescribed by current dosing guidelines. This is in contrast to previous reports and is to be considered highly important information with respect to the PK profile of this widely used drug. Despite this, azithromycin's clinical efficacy is to date unquestioned and might be explained not only by its high intracellular penetration and phagocyte-driven targeted delivery to infected sites but also by prolonged subinhibitory drug concentration exerting modulatory influence on bacterial virulence factors. Further research is necessary to better understand the implications of subinhibitory azithromycin drug concentrations on antibacterial effects and the emergence of bacterial resistance.
